About

FibroDx is a clinical-stage biopharmaceutical company developing radiopharmaceuticals for fibrotic diseases such as pulmonary fibrosis, cardiac fibrosis, hepatic fibrosis, renal fibrosis and cancers with fibrotic stroma.

The company is advancing its 1st generation tracer BOT5035 through phase 1/2  clinical PET-imaging trials targeting fibrogenic cells in patients with pulmonary or cardiac fibrosis.

Clinical trials with our 2nd generation tracer BOT1712, targeting PDGFRB-expressing cells in hepatic fibrosis and colon cancer, are expected to start in 2023.

BiOrion’s technology platform is based on the screening and selection of camelid-derived single domain antibodies (also known as VHHs or nanobodies) for selected membrane-bound proteins and receptors on myofibroblasts such as PDGFRA, PDGFRB, EGFR, IGF-2R and FAP. Eventually the platform allows for a theranostic approach using the same single domain antibody for patient identification,  targeted therapy and disease monitoring.